A Death for Guillain-Barrè Syndrome After Receiving a COVID-19 Vaccine: A Case Report

Antonio Coviello,Carmine Iacovazzo,Maria Vargas,Concetta Posillipo,Francesco Sagnelli,Pasquale Diglio,Dario Cirillo,Giuseppe Servillo
DOI: https://doi.org/10.1177/11795476241274692
2024-10-05
Abstract:The virus SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) causes COVID-19, a potentially fatal disease. The COVID-19 vaccine is indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2. We reported the case of a 66-year-old woman with a medical history of hypertension and anxious-depressive syndrome who developed Guillain Barré Syndrome (GBS) 4 weeks after receiving the COVID-19 vaccine. During the patient's hospital stay, they received cycles of high-dose intravenous immunoglobulin (IVIG) and plasmapheresis treatments.. Despite the treatment, a deterioration of respiratory function led the patient to premature mortality.
What problem does this paper attempt to address?